This Medudy course is a video tutorial for physicians on the topic of "Treatment of advanced prostate cancer: The ARAMIS study."
Prof. Dr. Martin Bögemann, senior physician for urology and pediatric urology at Münster University Hospital, presents the ARAMIS study investigating the efficacy and safety of darolutamide in non-metastatic, castration-resistant prostate cancer.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Bayer.
At the end of this training you will know:
- the design and inclusion criteria of the ARAMIS study, which investigated darolutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
- the significant prolongation of metastasis-free survival (MFS), the primary endpoint of the ARAMIS study
- the positive results in terms of overall survival (OS) as an important secondary endpoint.
- the safety profile and good tolerability of darolutamide compared to placebo based on data from the ARAMIS study.
